Your email has been successfully added to our mailing list.

×
0.000320081940976963 6.40163881953198E-05 -6.40163881953198E-05 -0.00108827859932135 -0.00608155687856084 -0.00480122911465335 -0.00448114717367639 -0.00377696690352732
Stock impact report

Cancer Concerns Are a New Worry for Gene Therapy. BioMarin Stock Is Falling. [Barron's]

BioMarin Pharmaceutical Inc. (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Company Research Source: Barrons
The company’s stock (ticker: BMRN) fell 7.5% Tuesday morning, to $78.60, on news that the U.S. Food and Drug Administration had placed a hold on the clinical trial of a BioMarin therapy for a congenital metabolic disorder called phenylketonuria. In its announcement, released Monday,... Show less Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BMRN alerts
Opt-in for
BMRN alerts

from News Quantified
Opt-in for
BMRN alerts

from News Quantified